Weickhardt et al. observed that the increased expression of phosphorylated HER3 is a key mechanism in the development of resistance to FGFR inhibitors in FGFR3 fused bladder cancers [37]. The gene discussed is FGFR3; the disease is urinary bladder carcinoma.